The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among
these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the …

… Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that blocks
programmed death ligand 1 (PD-L1) binding to programmed death 1 (PD-1) and CD80, allowing T …

Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer (NSCLC) …

… Durvalumab is a selective, high-affinity, engineered, human IgG1 monoclonal antibody that
blocks PD-L1 binding to PD-1 and CD80, allowing T cells to recognize and kill tumor cells. …

Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer
immunity, improved overall survival in patients with previously treated non-small-cell lung …

… -1 may also modulate immunity in a T-cell–independent manner. … of inhibitory kinases involved
in T-cell proliferation, adhesion… response of T cells upon antigen exposure and inducing T-…

Background Alectinib—a highly selective, CNS-active, ALK inhibitor—showed promising
clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK-…

Rationale: Electronic noses are successfully used in commercial applications, including
detection and analysis of volatile organic compounds in the food industry. Objectives: We …

Background: The concept behind cancer treatment has evolved over the past decade from
systemic, nonspecific, high-dose chemotherapy to targeted therapy and the introduction of …

Purpose Crizotinib confers improved progression-free survival compared with chemotherapy
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …